Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Dimethaid Research Articles

CEO ousted at Dimethaid, replaced by German doctor Henrich Guntermann

4 October 2004

Pennsaid launched in Italy

23 June 2003

Dimethaid's Pennsaid launched in Canada

9 June 2003

Dimethaid closes C$9.3M rights offer

28 April 2003

Dimethaid rights offering application continues

17 March 2003

Dimethaid's Pennsaid cleared in Italy

10 March 2003

Dimethaid's Pennsaid held up in Canada

18 February 2002

Dimethaid gets additional EU commitments for Pennsaid

3 October 2001

Dimethaid applies for Pennsaid approval in EU

17 May 2001

Dimethaid seeks EU approval for Pennsaid

30 January 2001

Provalis to market Dimethaid's Pennsaid in UK

11 January 2001

Dimethaid files for Pennsaid OK in Canada

26 October 2000

Dimethaid Research acquires manufacturing plant in Quebec

16 February 2000

Positive Phase III for Dimethaid's Pennsaid

20 September 1999

Dimethaid's Immune Modulator WF10

19 March 1998

Majors Moving Away From Acquisitions & Mergers

12 January 1998

Majors Moving Away From Acquisitions & Mergers

6 January 1998

Dimethaid Ups Stake In Oxo Chemie

4 April 1997

Dimethaid Research File For Canadian Pennsaid Approval

4 November 1996

Dimethaid To Acquire Stake In Oxo Chemie

1 July 1996

Dimethaid Trials In Canada

27 March 1995

TRIMEL FILES LAW SUIT

1 November 1993

OXO JOINT VENTURE

12 July 1993

Showing 1-23 of 23 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS